Drug Profile
Research programme: diabetes therapeutics - Egret Pharma/Theracos
Alternative Names: THR-5XXXLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Egret Pharma; Theracos
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)